These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 16934768)

  • 1. Resolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors.
    Papakostas GI; Nutt DJ; Hallett LA; Tucker VL; Krishen A; Fava M
    Biol Psychiatry; 2006 Dec; 60(12):1350-5. PubMed ID: 16934768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resolution of sleepiness and fatigue: a comparison of bupropion and selective serotonin reuptake inhibitors in subjects with major depressive disorder achieving remission at doses approved in the European Union.
    Cooper JA; Tucker VL; Papakostas GI
    J Psychopharmacol; 2014 Feb; 28(2):118-24. PubMed ID: 24352716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: a meta-analysis of individual patient data from 10 double-blind, randomized clinical trials.
    Papakostas GI; Trivedi MH; Alpert JE; Seifert CA; Krishen A; Goodale EP; Tucker VL
    J Psychiatr Res; 2008 Jan; 42(2):134-40. PubMed ID: 17631898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies.
    Papakostas GI; Stahl SM; Krishen A; Seifert CA; Tucker VL; Goodale EP; Fava M
    J Clin Psychiatry; 2008 Aug; 69(8):1287-92. PubMed ID: 18605812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study.
    Dunlop BW; Crits-Christoph P; Evans DL; Hirschowitz J; Solvason HB; Rickels K; Garlow SJ; Gallop RJ; Ninan PT
    J Clin Psychopharmacol; 2007 Dec; 27(6):614-9. PubMed ID: 18004129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative antidepressant efficacy of bupropion and the selective serotonin reuptake inhibitors in major depressive disorder: gender-age interactions.
    Papakostas GI; Kornstein SG; Clayton AH; Soares CN; Hallett LA; Krishen A; Tucker VL
    Int Clin Psychopharmacol; 2007 Jul; 22(4):226-9. PubMed ID: 17519646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.
    Clayton AH; Baker RA; Sheehan JJ; Cain ZJ; Forbes RA; Marler SV; Marcus R; Berman RM; Thase ME
    BMC Res Notes; 2014 Jul; 7():459. PubMed ID: 25037144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the Efficacy and Safety of Aripiprazole Versus Bupropion Augmentation in Patients With Major Depressive Disorder Unresponsive to Selective Serotonin Reuptake Inhibitors: A Randomized, Prospective, Open-Label Study.
    Cheon EJ; Lee KH; Park YW; Lee JH; Koo BH; Lee SJ; Sung HM
    J Clin Psychopharmacol; 2017 Apr; 37(2):193-199. PubMed ID: 28129308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue.
    Ninan PT; Hassman HA; Glass SJ; McManus FC
    J Clin Psychiatry; 2004 Mar; 65(3):414-20. PubMed ID: 15096082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials.
    Thase ME; Haight BR; Richard N; Rockett CB; Mitton M; Modell JG; VanMeter S; Harriett AE; Wang Y
    J Clin Psychiatry; 2005 Aug; 66(8):974-81. PubMed ID: 16086611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bupropion as an augmenting agent in patients of depression with partial response.
    Gulrez G; Badyal DK; Deswal RS; Sharma A
    Basic Clin Pharmacol Toxicol; 2012 Mar; 110(3):227-30. PubMed ID: 21895979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness.
    Fava M; Thase ME; DeBattista C
    J Clin Psychiatry; 2005 Jan; 66(1):85-93. PubMed ID: 15669893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot randomized clinical trial of an SSRI vs bupropion: effects on suicidal behavior, ideation, and mood in major depression.
    Grunebaum MF; Ellis SP; Duan N; Burke AK; Oquendo MA; John Mann J
    Neuropsychopharmacology; 2012 Feb; 37(3):697-706. PubMed ID: 21993207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Open-label study of adjunct modafinil for the treatment of patients with fatigue, sleepiness, and major depression treated with selective serotonin reuptake inhibitors.
    Konuk N; Atasoy N; Atik L; Akay O
    Adv Ther; 2006; 23(4):646-54. PubMed ID: 17050507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study.
    Safarinejad MR
    BJU Int; 2010 Sep; 106(6):840-7. PubMed ID: 20067456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symptoms of fatigue and sleepiness in major depressive disorder.
    Baldwin DS; Papakostas GI
    J Clin Psychiatry; 2006; 67 Suppl 6():9-15. PubMed ID: 16848671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies.
    Clayton AH; Croft HA; Horrigan JP; Wightman DS; Krishen A; Richard NE; Modell JG
    J Clin Psychiatry; 2006 May; 67(5):736-46. PubMed ID: 16841623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of SSRI-induced female sexual dysfunction by adjunctive bupropion in menstruating women: a double-blind, placebo-controlled and randomized study.
    Safarinejad MR
    J Psychopharmacol; 2011 Mar; 25(3):370-8. PubMed ID: 20080928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SSRI versus bupropion effects on symptom clusters in suicidal depression: post hoc analysis of a randomized clinical trial.
    Grunebaum MF; Keilp JG; Ellis SP; Sudol K; Bauer N; Burke AK; Oquendo MA; Mann JJ
    J Clin Psychiatry; 2013 Sep; 74(9):872-9. PubMed ID: 24107760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression.
    Fava M; Schaefer K; Huang H; Wilson A; Iosifescu DV; Mischoulon D; Wessel TC
    J Clin Psychiatry; 2011 Apr; 72(4):473-9. PubMed ID: 21208574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.